Beihai Kangcheng faced pressure on stock valuation and tried...

Beihai Kangcheng faced pressure on stock valuation and tried to increase the level of commercialization, but net loss did not shrink significantly. The company's development relies on high-cost financing, so consider listing on the US NASDAQ. There are differences in business model judgments in the Hong Kong stock market, and the US stock market is more mature in valuing research and development of rare disease treatments. However, if Beihai Kangcheng goes public in the US, it will be difficult for it to immediately receive widespread market attention.